Hemodynamic-GUIDEd Management of Heart Failure
GUIDE-HF
1 other identifier
interventional
2,358
2 countries
129
Brief Summary
The GUIDE-HF IDE clinical trial is intended to demonstrate the effectiveness of the CardioMEMS™ HF System in an expanded patient population including heart failure (HF) patients outside of the present indication, but at risk for future HF events or mortality.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable heart-failure
Started Mar 2018
Longer than P75 for not_applicable heart-failure
129 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
December 12, 2017
CompletedFirst Posted
Study publicly available on registry
January 2, 2018
CompletedStudy Start
First participant enrolled
March 15, 2018
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 17, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
May 17, 2023
CompletedResults Posted
Study results publicly available
August 7, 2025
CompletedAugust 7, 2025
July 1, 2025
5.2 years
December 12, 2017
January 30, 2025
July 18, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (8)
(Randomized Arm) Composite Outcome of (1) HFHs, (2) Intravenous Diuretic Visits, and (3) All-cause Mortality
The composite of: 1. The number of recurrent heart failure hospitalizations (HFHs) 2. The number of heart failure (HF) emergency department/hospital outpatient observation visits for intravenous diuretic therapy (ED/OP) 3. The number of deaths of any cause added together with equal weighting into a total number of events
12 months post-implantation (395 days after implant date)
(Randomized Arm) Composite Outcome of (1) HFHs, (2) Intravenous Diuretic Visits, and (3) All-cause Mortality [Follow-up Based COVID-19 Sensitivity Analysis]
The composite of: 1. The number of recurrent heart failure hospitalizations (HFHs) 2. The number of heart failure (HF) emergency department/hospital outpatient observation visits for intravenous diuretic therapy (ED/OP) 3. The number of deaths of any cause added together with equal weighting into a total number of events.
The COVID-19 pandemic occurred during follow-up after enrollment of all subjects. Events were analyzed through March 13, 2020 for pre-COVID-19 (median follow-up: 8.4 months) and after March 13, 2020 for during COVID-19 (median follow-up: 5.2 months).
(Randomized Arm) Composite Outcome of (1) HFHs, (2) Intravenous Diuretic Visits, and (3) All-cause Mortality [Subject Based COVID-19 Sensitivity Analysis]
The composite of: 1. The number of recurrent heart failure hospitalizations (HFHs) 2. The number of heart failure (HF) emergency department/hospital outpatient observation visits for intravenous diuretic therapy (ED/OP) 3. The number of deaths of any cause added together with equal weighting into a total number of events.
12 Months Post Implantation
(Randomized Arm) Composite Outcome of (1) HFHs, (2) Intravenous Diuretic Visits, and (3) All-cause Mortality [Event Based COVID-19 Sensitivity Analysis]
The composite of: 1. The number of recurrent heart failure hospitalizations (HFHs) 2. The number of heart failure (HF) emergency department/hospital outpatient observation visits for intravenous diuretic therapy (ED/OP) 3. The number of deaths of any cause added together with equal weighting into a total number of events.
12 Months Post-Implantation
(Single Arm) Composite Outcome of (1) HFHs, (2) Intravenous Diuretic Visits, and (3) All-cause Mortality
The composite outcome of: 1. The number of recurrent heart failure hospitalizations (HFHs) 2. The number of emergency department/hospital outpatient observation visits for intravenous diuretic therapy 3. The number of deaths of any cause added together with equal weighting into a total number of events
12 months post-implantation (395 days after implant date)
(Single Arm) Composite Outcome of (1) HFHs, (2) Intravenous Diuretic Visits, and (3) All-cause Mortality [Follow-up Based COVID-19 Sensitivity Analysis]
The composite outcome of: 1. The number of recurrent heart failure hospitalizations (HFHs) 2. The number of emergency department/hospital outpatient observation visits for intravenous diuretic therapy 3. The number of deaths of any cause added together with equal weighting into a total number of events
Events were analyzed through March 13, 2020 for pre-COVID-19 analysis (median follow-up: 5.4 months) and from March 13, 2020 through the end of subject's follow-up for during COVID-19 analysis (median follow-up: 11.2 months).
(Single Arm) Composite Outcome of (1) HFHs, (2) Intravenous Diuretic Visits, and (3) All-cause Mortality [Subject Based COVID-19 Sensitivity Analysis]
The composite outcome of: 1. The number of recurrent heart failure hospitalizations (HFHs) 2. The number of emergency department/hospital outpatient observation visits for intravenous diuretic therapy 3. The number of deaths of any cause added together with equal weighting into a total number of events
12 Months Post Implantation
(Single Arm) Composite Outcome of (1) HFHs, (2) Intravenous Diuretic Visits, and (3) All-cause Mortality [Event Based COVID-19 Sensitivity Analysis]
The composite outcome of: 1. The number of recurrent heart failure hospitalizations (HFHs) 2. The number of emergency department/hospital outpatient observation visits for intravenous diuretic therapy 3. The number of deaths of any cause added together with equal weighting into a total number of events
12 Months Post Implantation
Secondary Outcomes (43)
(Randomized Arm) Composite Outcome of (1) HFHs and (2) Intravenous Diuretic Visits
12 months post-implantation
(Randomized Arm) Composite Outcome of (1) HFHs and (2) Intravenous Diuretic Visits [Follow-up Based COVID-19 Sensitivity Analysis)
The COVID-19 pandemic occurred during follow-up after enrollment of all subjects. Events were analyzed through March 13, 2020 for pre-COVID-19 (median follow-up: 8.4 months) and after March 13, 2020 for during COVID-19 (median follow-up: 5.2 months).
(Randomized Arm) Composite Outcome of (1) HFHs and (2) Intravenous Diuretic Visits [Subject Based COVID-19 Sensitivity Analysis)
12 Months Post Implantation
(Randomized Arm) Composite Outcome of (1) HFHs and (2) Intravenous Diuretic Visits [Event Based COVID-19 Sensitivity Analysis)
12 Months Post Implantation
(Randomized Arm) HFHs
12 months post-implantation
- +38 more secondary outcomes
Other Outcomes (27)
(Randomized Arm) Cardiovascular Mortality
12 months post-implantation
(Randomized Arm) All-cause Hospitalizations
12 months post-implantation
(Randomized Arm) Frequency of Subject PA Pressure Uploads
12 months post-implantation
- +24 more other outcomes
Study Arms (3)
Randomized Arm - Treatment Group
EXPERIMENTALManagement of subjects based on pulmonary artery (PA) pressure information derived from the CardioMEMS™ HF System. All subjects will receive a CardioMEMS™ HF System.
Randomized Arm - Control Group
EXPERIMENTALManagement of subjects per standard of care (signs, symptoms, weight etc.) without knowledge of PA pressure information derived from the CardioMEMS™ HF System. All subjects will receive a CardioMEMS™ HF System.
Single Arm
EXPERIMENTALManagement of subjects based on PA pressure information derived from the CardioMEMS™ HF System. All subjects will receive a CardioMEMS™ HF System.
Interventions
The CardioMEMS™ HF System is comprised of a lead-less, battery-less pressure sensor permanently implanted in the PA, which remotely transmits PA pressure measurements from the patient's home to a secure website. Healthcare professionals are able to access these measurements and associated waveforms to remotely guide individualization of medical management for their patients with chronic HF.
Eligibility Criteria
You may qualify if:
- Diagnosis and treatment for heart failure (HF) (regardless of left ventricular ejection fraction (LVEF)) for \> 90 days prior to the date of consent:
- a. Subjects should be on stable, optimally titrated medical therapy for at least 30 days, as recommended according to current American Heart Association (AHA)/American College of Cardiology (ACC) guidelines as standard-of-care for HF therapy in the United States, with any intolerance documented.
- GUIDE-HF Randomized Arm Only: NYHA Class II, III or IV HF symptoms documented within 30 days prior to consent.
- GUIDE-HF Single Arm Only: NYHA Class III HF symptoms documented within 30 days prior to consent.
- HF hospitalization (HFH) within 12 months prior to consent and/or elevated N-terminal pro-Brain Natriuretic Peptide (NT-proBNP) (or Brain Natriuretic Peptide (BNP)) within 30 days prior to consent defined as:
- Subjects with LVEF ≤ 40%: NT-proBNP ≥ 1000 pg/mL (or BNP ≥ 250 pg/mL).
- Subjects with LVEF \> 40%: NT-proBNP ≥ 700 pg/mL (or BNP ≥ 175 pg/mL).
- Thresholds for NT-proBNP and BNP (for both LVEF ≤ 40% and LVEF \> 40%) will be corrected for body mass index (BMI) using a 4% reduction per BMI unit over 25 kg/m2
- ≥ 18 years of age
- Chest circumference of \< 65 inches, if BMI is \> 35 kg/m2
- Written informed consent obtained from subject
- Willing and able to upload pulmonary artery (PA) pressure information and comply with the follow-up requirements
You may not qualify if:
- Intolerance to all neuro-hormonal antagonists (i.e., intolerance to angiotensin converting enzyme-inhibitors (ACE-I), angiotensin receptor blockers (ARB), angiotensin-neprilysin inhibitors (ARNi), hydralazine/isosorbide dinitrate and beta-blockers)
- ACC/AHA Stage D refractory HF (including having received or currently receiving pharmacologic circulatory support with inotropes)
- Received or are likely to receive an advanced therapy (e.g., mechanical circulatory support or cardiac transplant) in the next 12 months
- NYHA Class IV HF patients with:
- Continuous or chronic use of scheduled intermittent inotropic therapy for HF and an INTERMACS level of ≤ 4, OR
- Persistence of fluid overload with maximum (or dose equivalent) diuretic intervention
- Glomerular Filtration Rate (eGFR) \< 25 mL/min and non-responsive to diuretic therapy, or receiving chronic dialysis
- Inability to tolerate or receive dual antiplatelet therapy or anticoagulation therapy for one month post-implantation
- Significant congenital heart disease that has not been repaired and would prevent implantation of the CardioMEMS™ PA Sensor
- Implanted with mechanical right heart valve(s)
- Unrepaired severe valvular disease
- Pregnant or planning to become pregnant in the next 12 months
- An active, ongoing infection, defined as being febrile, an elevated white blood cell count, on intravenous antibiotics, and/or positive cultures (blood, sputum or urine).
- History of current or recurrent (≥ 2 episodes within 5 years prior to consent) pulmonary emboli and/or deep vein thrombosis
- Major cardiovascular event (e.g., unstable angina, myocardial infarction, percutaneous coronary intervention, open heart surgery, or stroke, etc.) within 90 days prior to consent
- +4 more criteria
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (129)
Banner-University Medical Center Phoenix
Phoenix, Arizona, 85006, United States
Arizona Cardiovascular Research Center
Phoenix, Arizona, 85016, United States
Phoenix Cardiovascular Research Group
Phoenix, Arizona, 85018, United States
University of Arizona
Tucson, Arizona, 85719, United States
Washington Regional Medical Center
Fayetteville, Arkansas, 72703, United States
Baptist Health Medical Center
Little Rock, Arkansas, 72205, United States
Arkansas Heart Hospital
Little Rock, Arkansas, 72211, United States
John Muir Medical Center
Concord, California, 94520, United States
Adventist Health St. Helena
Deer Park, California, 94574, United States
Scripps Health
La Jolla, California, 92037, United States
University of California at San Diego (UCSD) Medical Center
La Jolla, California, 92037, United States
USC University Hospital
Los Angeles, California, 90033, United States
Ronald Reagan UCLA Medical Center
Los Angeles, California, 90095, United States
Eisenhower Medical Center
Rancho Mirage, California, 92270, United States
Sutter Medical Center, Sacramento
Sacramento, California, 95816, United States
Mercy Medical Group - Cardiology
Sacramento, California, 95819, United States
San Diego Cardiac Center
San Diego, California, 92123, United States
California Pacific Medical Center - Van Ness Campus
San Francisco, California, 94109, United States
Ventura Cardiology Consultants
Ventura, California, 93003, United States
University of Colorado Hospital
Aurora, Colorado, 80045, United States
North Colorado Medical Center
Greeley, Colorado, 80631, United States
South Denver Cardiology Associates PC
Littleton, Colorado, 80120, United States
Hartford Hospital
Hartford, Connecticut, 06106, United States
Yale New Haven Hospital
New Haven, Connecticut, 06510, United States
George Washington University Hospital
Washington D.C., District of Columbia, 20037, United States
Bethesda Memorial Hospital
Boynton Beach, Florida, 33466, United States
Morton Plant Hospital
Clearwater, Florida, 33756, United States
Memorial Regional Hospital
Hollywood, Florida, 33020, United States
First Coast Cardiovascular Institute
Jacksonville, Florida, 32216, United States
Memorial Hospital Jacksonville
Jacksonville, Florida, 32216, United States
Advent Health Orlando
Orlando, Florida, 32803, United States
Tampa General Hospital
Tampa, Florida, 33606, United States
Piedmont Athens Regional Medical Center
Athens, Georgia, 30606, United States
University Hospital
Augusta, Georgia, 30901, United States
WellStar Kennestone Hospital
Marietta, Georgia, 30060, United States
Northshore University HealthSystem
Evanston, Illinois, 60201, United States
Advocate Health and Hospitals Corporation
Oakbrook Terrace, Illinois, 60181, United States
St. Vincent Hospital
Indianapolis, Indiana, 46240, United States
Heart Center of Lake County
Merrillville, Indiana, 46410, United States
Iowa Heart Center
West Des Moines, Iowa, 50266, United States
Kansas University Medical Center
Kansas City, Kansas, 66160, United States
Cardiovascular Research Institute of Kansas
Wichita, Kansas, 67226, United States
Our Lady of the Lake Hospital
Baton Rouge, Louisiana, 70808, United States
Cardiovascular Institute of the South
Houma, Louisiana, 70361, United States
Louisiana State University Health Sciences Center
New Orleans, Louisiana, 70112, United States
Ochsner Medical Center
New Orleans, Louisiana, 70121, United States
Advanced Cardiovascular Specialists
Shreveport, Louisiana, 71105, United States
Brigham and Women's Hospital
Boston, Massachusetts, 02115, United States
University of Massachusetts
Worcester, Massachusetts, 01655, United States
University of Michigan
Ann Arbor, Michigan, 48104, United States
McLaren Health Care Corporation
Auburn Hills, Michigan, 48326, United States
Henry Ford Hospital
Detroit, Michigan, 48202, United States
MidMichigan Medical Center-Midland
Midland, Michigan, 48640, United States
Providence Hospital
Southfield, Michigan, 48075, United States
Minneapolis Heart Institute
Minneapolis, Minnesota, 55407, United States
University of Minnesota Medical Center Fairview
Minneapolis, Minnesota, 55455, United States
Mayo Clinic
Rochester, Minnesota, 55905, United States
St. Cloud Hospital
Saint Cloud, Minnesota, 56303, United States
St. Luke's Hospital
Kansas City, Missouri, 64111, United States
North Kansas City Hospital
North Kansas City, Missouri, 64116, United States
Mercy Hospital St. Louis
St Louis, Missouri, 63141, United States
BryanLGH Heart Institute
Lincoln, Nebraska, 68506, United States
University of Nebraska Medical Center
Omaha, Nebraska, 68198, United States
Renown Regional Medical Center
Reno, Nevada, 89502, United States
Catholic Medical Center
Manchester, New Hampshire, 03102, United States
Deborah Heart and Lung Center
Browns Mills, New Jersey, 08015, United States
Saint Barnabas Medical Center
Livingston, New Jersey, 07039, United States
Lourdes Cardiology Services
Voorhees Township, New Jersey, 08043, United States
New Mexico Heart Institute
Albuquerque, New Mexico, 87102, United States
New York University Hospital
New York, New York, 10016, United States
Mount Sinai Hospital
New York, New York, 10019, United States
New York-Presbyterian/Columbia University
New York, New York, 10032, United States
Hudson Valley Cardiovascular Practice, P.C.
Poughkeepsie, New York, 12601, United States
Rochester General Hospital
Rochester, New York, 14621, United States
St. Francis Hospital
Roslyn, New York, 11576, United States
Carolinas Medical Center
Charlotte, North Carolina, 28203, United States
Vidant Medical Center
Greenville, North Carolina, 27835, United States
NC Heart and Vascular Research
Raleigh, North Carolina, 27607, United States
WakeMed Hospital
Raleigh, North Carolina, 27610, United States
Akron City Hospital
Akron, Ohio, 44309, United States
University Hospitals Cleveland Medical Center
Cleveland, Ohio, 44106, United States
The Cleveland Clinic Foundation
Cleveland, Ohio, 44195, United States
Ohio State University
Columbus, Ohio, 43210, United States
Ohio Health Research Institute
Columbus, Ohio, 43214, United States
St. Elizabeth Health Center
Youngstown, Ohio, 44501, United States
Integris Baptist Medical Center
Oklahoma City, Oklahoma, 73112, United States
Oklahoma Heart Hospital South
Oklahoma City, Oklahoma, 73135, United States
Oklahoma Heart Institute at Utica
Tulsa, Oklahoma, 74133, United States
Providence Heart and Vascular
Portland, Oregon, 97225, United States
Abington Memorial Hospital
Abington, Pennsylvania, 19001, United States
Pinnacle Health System
Harrisburg, Pennsylvania, 17105, United States
Penn State Milton S. Hershey Medical Center
Hershey, Pennsylvania, 17033, United States
Lancaster General Hospital
Lancaster, Pennsylvania, 17603, United States
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
Albert Einstein Medical Center
Philadelphia, Pennsylvania, 19141, United States
Allegheny General Hospital - ASRI
Pittsburgh, Pennsylvania, 15212, United States
The Reading Hospital and Medical Center
West Reading, Pennsylvania, 19611, United States
Main Line Health Center/Lankenau Hospital
Wynnewood, Pennsylvania, 19096, United States
Rhode Island Hospital
Providence, Rhode Island, 02903, United States
Prisma Health-Midlands
Columbia, South Carolina, 29203, United States
Greenville Health System
Greenville, South Carolina, 29605, United States
Sanford USD Medical Center
Sioux Falls, South Dakota, 57117, United States
Tennova Healthcare - Turkey Creek Medical Center
Knoxville, Tennessee, 37920, United States
Methodist University Hospital
Memphis, Tennessee, 38104, United States
St Thomas Hospital
Nashville, Tennessee, 37205, United States
Vanderbilt University Medical Center
Nashville, Tennessee, 37232, United States
Acension Texas Cardiovascular
Austin, Texas, 78705, United States
Austin Heart
Austin, Texas, 78756, United States
Baylor University Hospital
Dallas, Texas, 75246, United States
John Peter Smith Hospital
Fort Worth, Texas, 76104, United States
Park Plaza Hospital
Houston, Texas, 77004, United States
CHI St. Luke's Health Baylor College of Medicine Med. Ctr.
Houston, Texas, 77030, United States
Memorial Hermann Hospital
Houston, Texas, 77030, United States
The Methodist Hospital
Houston, Texas, 77030, United States
Methodist Healthcare System of San Antonio
San Antonio, Texas, 78229, United States
Virginia Heart - The Cardiovascular Group, P.C.
Falls Church, Virginia, 22042, United States
Sentara Norfolk General Hospital
Norfolk, Virginia, 23507, United States
Bon Secours Heart & Vascular Institute
Richmond, Virginia, 23226, United States
Winchester Medical Center
Winchester, Virginia, 22601, United States
Providence Everett Medical Center
Everett, Washington, 98206, United States
Swedish Medical Center - Heart & Vascular
Seattle, Washington, 98122, United States
University of Washington Medical Center
Seattle, Washington, 98195, United States
Aurora Medical Group
Milwaukee, Wisconsin, 53215, United States
Waukesha Memorial Hospital
Waukesha, Wisconsin, 53188, United States
Aspirus Wausau Hospital
Wausau, Wisconsin, 54401, United States
Foothills Medical Centre
Calgary, Alberta, T2N2T9, Canada
Vancouver General Hospital (U of BC)
Vancouver, British Columbia, V5Z 1M9, Canada
Southlake Regional Health Centre
Newmarket, Ontario, L3Y 2P9, Canada
Toronto General Hospital
Toronto, Ontario, M5G 2C4, Canada
Related Publications (5)
Zile MR, Abraham WT, Stevenson LW, Costanzo MR, Angermann CE, Mehra MR, Desai AS, Ducharme A, Johnson N, Henderson J, Lindenfeld J. Relationship Between Remote, Ambulatory Pulmonary Artery Pressures, and All-Cause Mortality in Patients With Chronic Heart Failure. Circ Heart Fail. 2025 Jun;18(6):e012754. doi: 10.1161/CIRCHEARTFAILURE.124.012754. Epub 2025 Apr 14.
PMID: 40223608DERIVEDDesai AS, Maisel A, Mehra MR, Zile MR, Ducharme A, Paul S, Sears SF, Smart F, Bhatt K, Krim S, Henderson J, Johnson N, Adamson PB, Costanzo MR, Lindenfeld J; GUIDE-HF Investigators. Hemodynamic-Guided Heart Failure Management in Patients With Either Prior HF Hospitalization or Elevated Natriuretic Peptides. JACC Heart Fail. 2023 Jun;11(6):691-698. doi: 10.1016/j.jchf.2023.01.007. Epub 2023 Apr 12.
PMID: 37286262DERIVEDZile MR, Mehra MR, Ducharme A, Sears SF, Desai AS, Maisel A, Paul S, Smart F, Grafton G, Kumar S, Nossuli TO, Johnson N, Henderson J, Adamson PB, Costanzo MR, Lindenfeld J. Hemodynamically-Guided Management of Heart Failure Across the Ejection Fraction Spectrum: The GUIDE-HF Trial. JACC Heart Fail. 2022 Dec;10(12):931-944. doi: 10.1016/j.jchf.2022.08.012. Epub 2022 Oct 12.
PMID: 36456066DERIVEDZile MR, Desai AS, Costanzo MR, Ducharme A, Maisel A, Mehra MR, Paul S, Sears SF, Smart F, Chien C, Guha A, Guichard JL, Hall S, Jonsson O, Johnson N, Sood P, Henderson J, Adamson PB, Lindenfeld J. The GUIDE-HF trial of pulmonary artery pressure monitoring in heart failure: impact of the COVID-19 pandemic. Eur Heart J. 2022 Jul 14;43(27):2603-2618. doi: 10.1093/eurheartj/ehac114.
PMID: 35266003DERIVEDLindenfeld J, Zile MR, Desai AS, Bhatt K, Ducharme A, Horstmanshof D, Krim SR, Maisel A, Mehra MR, Paul S, Sears SF, Sauer AJ, Smart F, Zughaib M, Castaneda P, Kelly J, Johnson N, Sood P, Ginn G, Henderson J, Adamson PB, Costanzo MR. Haemodynamic-guided management of heart failure (GUIDE-HF): a randomised controlled trial. Lancet. 2021 Sep 11;398(10304):991-1001. doi: 10.1016/S0140-6736(21)01754-2. Epub 2021 Aug 27.
PMID: 34461042DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Limitations and Caveats
The COVID-19 pandemic affected the GUIDE-HF Randomized Arm study. The impact of COVID-19 on the primary endpoint and components was addressed through sensitivity analyses. Single Arm Total Efficacy Population includes implanted subjects not belonging to a qualifying criteria group.
Results Point of Contact
- Title
- Fei San Lee, PhD, Sr Clinical Research Scientist
- Organization
- Abbott
Study Officials
- STUDY DIRECTOR
Nessa Johnson, PhD
Abbott
Publication Agreements
- PI is Sponsor Employee
- No
- Restrictive Agreement
- No
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- PARTICIPANT
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
December 12, 2017
First Posted
January 2, 2018
Study Start
March 15, 2018
Primary Completion
May 17, 2023
Study Completion
May 17, 2023
Last Updated
August 7, 2025
Results First Posted
August 7, 2025
Record last verified: 2025-07
Data Sharing
- IPD Sharing
- Will not share